IL151992A0 - Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists - Google Patents
Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonistsInfo
- Publication number
- IL151992A0 IL151992A0 IL15199201A IL15199201A IL151992A0 IL 151992 A0 IL151992 A0 IL 151992A0 IL 15199201 A IL15199201 A IL 15199201A IL 15199201 A IL15199201 A IL 15199201A IL 151992 A0 IL151992 A0 IL 151992A0
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- growth factor
- receptor antagonists
- vascular endothelial
- factor receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54077000A | 2000-03-31 | 2000-03-31 | |
PCT/US2001/010504 WO2001074296A2 (en) | 2000-03-31 | 2001-03-30 | Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IL151992A0 true IL151992A0 (en) | 2003-04-10 |
Family
ID=24156859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15199201A IL151992A0 (en) | 2000-03-31 | 2001-03-30 | Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1436000A2 (en) |
JP (1) | JP2004501070A (en) |
KR (1) | KR20020087453A (en) |
AU (1) | AU2001249736A1 (en) |
CA (1) | CA2404040A1 (en) |
CZ (1) | CZ20023518A3 (en) |
IL (1) | IL151992A0 (en) |
RU (1) | RU2002129574A (en) |
SK (1) | SK15302002A3 (en) |
WO (1) | WO2001074296A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0113757B8 (en) | 2000-09-11 | 2017-11-07 | Chiron Corp | quinolinone derivatives as tyrosine kinase inhibitors |
KR100847169B1 (en) | 2000-12-21 | 2008-07-17 | 글락소 그룹 리미티드 | Pyrimidineamines as angiogenesis modulators |
EP1416960A4 (en) * | 2001-07-13 | 2006-02-22 | Imclone Systems Inc | Vegfr-1 antibodies to treat breast cancer |
AU2003213687A1 (en) | 2002-03-04 | 2003-09-22 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
US7825132B2 (en) * | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
EP1539754A4 (en) | 2002-08-23 | 2009-02-25 | Novartis Vaccines & Diagnostic | Benzimidazole quinolinones and uses thereof |
WO2005021554A1 (en) | 2003-08-29 | 2005-03-10 | Pfizer Inc. | Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents |
BRPI0418102A (en) | 2003-12-23 | 2007-04-27 | Pfizer | quinoline derivatives |
JP6117225B2 (en) | 2011-11-02 | 2017-04-19 | アペクシジェン, インコーポレイテッド | Anti-KDR antibody and method of use thereof |
-
2001
- 2001-03-30 JP JP2001572042A patent/JP2004501070A/en not_active Withdrawn
- 2001-03-30 EP EP01922996A patent/EP1436000A2/en not_active Withdrawn
- 2001-03-30 SK SK1530-2002A patent/SK15302002A3/en not_active Application Discontinuation
- 2001-03-30 CZ CZ20023518A patent/CZ20023518A3/en unknown
- 2001-03-30 KR KR1020027013022A patent/KR20020087453A/en not_active Application Discontinuation
- 2001-03-30 WO PCT/US2001/010504 patent/WO2001074296A2/en not_active Application Discontinuation
- 2001-03-30 CA CA002404040A patent/CA2404040A1/en not_active Abandoned
- 2001-03-30 RU RU2002129574/15A patent/RU2002129574A/en not_active Application Discontinuation
- 2001-03-30 AU AU2001249736A patent/AU2001249736A1/en not_active Abandoned
- 2001-03-30 IL IL15199201A patent/IL151992A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
SK15302002A3 (en) | 2004-06-08 |
AU2001249736A1 (en) | 2001-10-15 |
EP1436000A2 (en) | 2004-07-14 |
WO2001074296A2 (en) | 2001-10-11 |
KR20020087453A (en) | 2002-11-22 |
CZ20023518A3 (en) | 2004-04-14 |
WO2001074296A3 (en) | 2004-05-06 |
CA2404040A1 (en) | 2001-10-11 |
RU2002129574A (en) | 2004-04-20 |
JP2004501070A (en) | 2004-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL157693A0 (en) | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist | |
HUP0201480A3 (en) | Treatment of refractory human tumors with epidermal growth factor receptor antagonists | |
SG117417A1 (en) | Variants of the angiogenic factor vascular endothelial cell growth factor: vegf | |
IL198800A0 (en) | Growth differentiation factor receptors, agonists and antagonists thereof and methods of using same | |
EP1385862A4 (en) | Vascular endothelial growth factor 2 | |
AU8298201A (en) | Sutures and coatings made from therapeutic absorbable glass | |
EP1313512A4 (en) | Vascular endothelial growth factor 2 | |
EP1487490A4 (en) | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist | |
AU9500201A (en) | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists | |
AU5023300A (en) | Vascular endothelial growth factor variants | |
IL149313A0 (en) | Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists | |
HUP0200827A2 (en) | Vascular endothelial cell growth factor variants and uses thereof | |
IL151992A0 (en) | Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists | |
AU2001277524A1 (en) | Novel use of inhibitors of the epidermal growth factor receptor | |
AU2003216389A8 (en) | Induction of hair growth with vascular endothelial growth factor | |
PL351794A1 (en) | 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists | |
HUP0101520A3 (en) | Biologically degradable cement exhibiting improved properties | |
HK1041500A1 (en) | Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt | |
IS5999A (en) | Bone growth factor | |
FR2826865B1 (en) | COTYLOIDIAN IMPLANT CUP | |
IL143451A0 (en) | NEW- β-AMIDE AND β-SULFONAMIDE CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | |
ZA200109347B (en) | Treatment of refractory human tumors with epidermal growth factor receptor antagonists. | |
AU1310201A (en) | Cdt6 can inhibit angiogenesis and tumor growth, and can induce or enhance the formation of structures containing collagen | |
GB9921046D0 (en) | Therapeutic antibody composition & use | |
TW412998U (en) | Structure of cup with heat-insulating effects |